Violation Tracker Parent Company Summary
|Top 5 Offense Groups (Groups Defined)||Penalty Total||Number of Records|
|Top 5 Primary Offense Types||Penalty Total||Number of Records|
|investor protection violation||$145,000,000||1|
|kickbacks and bribery||$78,647,876||3|
|False Claims Act and related||$33,700,000||2|
|price-fixing or anti-competitive practices||$17,500,000||1|
|accounting fraud or deficiencies||$11,000,000||2|
Parent-subsidiary linkages are based on relationships current as of the latest revision listed in the Update Log, which may vary from what was the case when a violation occurred. The penalty totals are adjusted to account for the fact that the individual entries below may include both agency records and settlement announcements for the same case; or else a penalty covering multiple locations may be listed in the individual records for each of the facilities. The totals are also adjusted to reflect cases in which federal and state or local agencies cooperated and issued separate announcements of the outcome. Duplicate or overlapping penalty amounts are marked with an asterisk in the list below.
Bausch & Lomb; BAUSCH AND LOMB; BIOVAIL; BIOVAIL AMERICAS; BIOVAIL PHARMACEUTICALS; ICN PHARMACEUTICALS; ISTA Pharmaceuticals, Inc.; Medicis Pharmaceutical Corporation; Salix Pharmaceuticals Inc.; Valeant Pharmaceuticals International, Inc.; Valeant Pharmaceuticals, Inc.
Subsidy Tracker data on financial assistance to this company by federal, state and local government agencies can be found here.
Individual Penalty Records:Click on the company or penalty amount for more information on each case.
|Company||Primary Offense Type||Year||Agency||Penalty Amount|
|Valeant Pharmaceuticals International, Inc.||investor protection violation||2017||MULTI-AG||$145,000,000|
|Salix Pharmaceuticals Inc.||kickbacks and bribery||2016||USAO||$54,000,000|
|ISTA Pharmaceuticals, Inc.||False Claims Act and related||2013||DOJ_CIVIL||$33,500,000|
|Biovail Pharmaceuticals Inc.||kickbacks and bribery||2009||USAO||$24,647,876|
|Bausch & Lomb||price-fixing or anti-competitive practices||2001||MULTI-AG||$17,500,000|
|Biovail Corporation||accounting fraud or deficiencies||2008||SEC||$10,000,000|
|Medicis Pharmaceutical Corporation||off-label or unapproved promotion of medical products||2007||DOJ_CIVIL||$9,800,000|
|Salix Pharmaceuticals Inc.||kickbacks and bribery||2016||MULTI-AG||(*) $7,470,000|
|Medicis Pharmaceutical||employment discrimination||2016||private lawsuit-federal||$7,150,000|
|ICN Pharmaceuticals, Inc.||fraud||2001||USAO||$5,600,000|
|Medicis Pharmaceutical Corporation||off-label or unapproved promotion of medical products||2007||MULTI-AG||(*) $4,000,000|
|Valeant Pharmaceuticals, Inc.||insurance violation||2018||CA-INS||$1,875,000|
|ICN Pharmaceuticals, Inc.||accounting fraud or deficiencies||2002||SEC||$1,000,000|
|ISTA Pharmaceuticals, Inc.||off-label or unapproved promotion of medical products||2013||MULTI-AG||(*) $390,253|
|Biovail||False Claims Act and related||2013||LA-AG||$200,000|
|VALEANT PHARMACEUTICALS INTERNATIONAL, INC.||benefit plan administrator violation||2016||EBSA||$10,001|
|BIOVAIL AMERICAS CORP.||benefit plan administrator violation||2012||EBSA||$10,001|
|BAUSCH AND LOMB PHARMACEUTICALS, INC.||workplace safety or health violation||2000||OSHA||$7,000|
|ICN Pharmaceuticals, Inc||economic sanction violation||2004||OFAC||$5,500|